Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
6.64
-0.04 (-0.60%)
Apr 23, 2026, 1:04 PM EDT - Market open
Fennec Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts that cover Fennec Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $14.5, which forecasts a 118.37% increase in the stock price over the next year. The lowest target is $13 and the highest is $18.
Price Target: $14.5 (+118.37%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Fennec Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $13 | Buy | Reiterates | $13 | +95.78% | Apr 16, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $18 | Buy | Initiates | $18 | +171.08% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +95.78% | Aug 21, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $13 → $14 | Strong Buy | Maintains | $13 → $14 | +110.84% | Aug 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +95.78% | May 20, 2025 |
Financial Forecast
Revenue This Year
73.72M
from 44.64M
Increased by 65.12%
Revenue Next Year
104.00M
from 73.72M
Increased by 41.08%
EPS This Year
0.43
from -0.34
EPS Next Year
1.09
from 0.43
Increased by 153.75%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 83.1M | 120.3M | |||
| Avg | 73.7M | 104.0M | |||
| Low | 61.1M | 80.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 86.2% | 63.2% | |||
| Avg | 65.1% | 41.1% | |||
| Low | 36.8% | 8.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.97 | 1.64 | |||
| Avg | 0.43 | 1.09 | |||
| Low | 0.16 | 0.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 280.8% | |||
| Avg | - | 153.8% | |||
| Low | - | 70.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.